

REMARKS

Claims 2-10 and 12-20 are pending in the application.

Election/Restriction

The Examiner has required restriction between the following inventions in the above-identified application:

Group I: Claims 3, 9-10, 13, and 19-20, drawn to a method of treating a subject by stimulating an effector T cell function, and a method of stimulating effector T cell function, comprising administering/contacting with an agent that downmodulates expression of a PSG-1, PSG-3, PSG-6, or PSG-9 gene;

Group II: Claims 4, 9-10, 14, and 19-20, drawn to a method of treating a subject by stimulating an effector T cell function, and a method of stimulating effector T cell function, comprising administering/contacting with an agent that downmodulates the activity of a PSG-1, PSG-3, PSG-6, or PSG-9 polypeptide;

Group III: Claims 5, 7-8, 15, and 17-18, drawn to a method of treating a subject by inhibiting effector T cell function, and a method of inhibiting effector T cell function, comprising administering/contacting with an agent that upmodulates expression of a PSG-1, PSG-3, PSG-6, or PSG-9 gene; and

Group IV: Claims 6-8, and 16-18, drawn to a method of treating a subject by inhibiting an effector T cell function, and a method of inhibiting effector T cell function, comprising administering/contacting with an agent that upmodulates the activity of a PSG-1, PSG-3, PSG-6, or PSG-9 polypeptide.

Applicants hereby elect Group IV (claims 6-8, and 16-18), drawn to methods of treating a subject by inhibiting an effector T cell function, and a method of inhibiting effector T cell function, comprising administering/contacting with an agent that upmodulates the activity of a PSG-1, PSG-3, PSG-6, or PSG-9 polypeptide), for prosecution in the present application, *without traverse*.

It is Applicants' understanding that, according to the Examiner's indication, "[c]laims 2 and 12 link(s) inventions I-IV. The restriction requirement between the linked inventions is subject to the non-allowance of the linking claim(s) 2 and 12. Upon the allowance of the linking

claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application”.

The Examiner has also required, under 35 U.S.C. §121, an election of the following species for prosecution on the merits, to which the claims will be restricted if no generic claim is finally held to be allowable:

- a) a specific gene/polypeptide, *i.e.*, PSG-1, PSG-3, PSG-6, or PSG-9;
- b) if Group III or Group IV is elected, a specific condition to be treated, *i.e.*, transplant, allergic response, or autoimmune disorder; and
- c) if Group I or Group II is elected, a specific condition to be treated, *i.e.*, infection or tumor.

Accordingly, within Group IV, Applicants hereby further elect, ***without traverse***, the species of:

- a) PSG-1; and
- b) an autoimmune disorder.

It is Applicants’ understanding that upon allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141, *et seq.*


Applicants reserve the right to traverse the above restriction with respect to non-elected Groups I-III in this or subsequent applications.

CONCLUSION

If a telephone conversation with Applicants' Attorney would expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' Attorney at (617) 227-7400.

Dated: March 1, 2007

Respectfully submitted,

By 
Megan E. Williams
Registration No. 43,270
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicants